Correction to: Orphanet Journal of Rare Diseases (2024) 19:86
10.1186/s13023-024-03097-x
Following publication of the original article [1], we have been notified that there should be a disclaimer published in the Acknowledgement note.
Acknowledgement note now is:
Acknowledgements
The authors would like to thank Sandra Retzky and Dionna Green for their input on this research project.
Acknowledgement note should be:
Acknowledgements
The authors would like to thank Sandra Retzky and Dionna Green for their input on this research project.
This manuscript reflects the views of the authors and should not be construed to represent FDA’s and the Department of Health and Human Services (HHS)’s views or policies.
Footnotes
The online version of the original article can be found at 10.1186/s13023-024-03097-x.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Mease et al. Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development. Orphanet J Rare Dis. 2024;19:86. 10.1186/s13023-024-03097-x. [DOI] [PMC free article] [PubMed]